(0.05%) 5 519.75 points
(0.10%) 39 884 points
(0.15%) 19 781 points
(-0.06%) $81.58
(0.60%) $2.83
(-0.27%) $2 338.10
(0.08%) $29.55
(0.39%) $1 005.70
(0.04%) $0.932
(-0.07%) $10.53
(-0.01%) $0.788
(-0.85%) $87.25
5.39% $ 0.540
Live Chart Being Loaded With Signals
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial...
Stats | |
---|---|
Dzisiejszy wolumen | 1.29M |
Średni wolumen | 667 554 |
Kapitalizacja rynkowa | 22.23M |
EPS | $-0.280 ( Q1 | 2024-05-13 ) |
Następna data zysków | ( $-0.350 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.480 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-22 | Ways Kirk | Buy | 30 000 | Stock Option (Right to Buy) |
2024-05-22 | Spiegelman Daniel K | Buy | 30 000 | Stock Option (Right to Buy) |
2024-05-22 | Simpson Camilla V | Buy | 30 000 | Stock Option (Right to Buy) |
2024-05-22 | Muralidhar Bali | Buy | 30 000 | Stock Option (Right to Buy) |
2024-05-22 | Grey Michael G | Buy | 30 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
1.67 |
Last 98 transactions |
Buy: 11 464 448 | Sell: 4 966 992 |
Wolumen Korelacja
Spruce Biosciences, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TBBK | 0.922 |
MDB | 0.913 |
GTLB | 0.905 |
CPSH | 0.896 |
HURC | 0.895 |
CCOI | 0.891 |
TNGX | 0.877 |
XERS | 0.872 |
ZS | 0.867 |
HDSN | 0.865 |
10 Najbardziej negatywne korelacje | |
---|---|
BNR | -0.883 |
CMPO | -0.876 |
ACT | -0.865 |
CTHR | -0.865 |
WHLR | -0.861 |
GLNG | -0.855 |
EH | -0.854 |
MGEE | -0.85 |
SWBI | -0.844 |
TIGO | -0.842 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Spruce Biosciences, Inc. Korelacja - Waluta/Towar
Spruce Biosciences, Inc. Finanse
Annual | 2023 |
Przychody: | $10.09M |
Zysk brutto: | $10.02M (99.31 %) |
EPS: | $-1.240 |
FY | 2023 |
Przychody: | $10.09M |
Zysk brutto: | $10.02M (99.31 %) |
EPS: | $-1.240 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-429 000 (0.00 %) |
EPS: | $-1.920 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.813 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej